



Fermiscan Holdings Limited

Level 5
48 Hunter Street
Sydney NSW 2000
Australia

t. +61 2 9245 4460
f. +61 2 9223 9622

www.fermiscan.com.au

ABN 51 000 689 725

ASX ANNOUNCEMENT

7 May 2009

Proxy and voting results of the Annual General Meeting of Fermiscan Holdings Limited ACN 000 689 725 held on Thursday 7 May 2009

The following information regarding the results of the Annual General Meeting of Fermiscan Holdings Limited held on 7 May 2009 is provided in accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act.

The first item of ordinary business was to receive and consider the financial and other reports for the year ended 31 December 2008. Shareholders were given the opportunity to raise questions about these reports at the meeting. In accordance with the Corporations Act, there was no need for shareholders to vote on, approve or adopt these reports.

Ordinary business item 2: To adopt the Remuneration Report.

"To adopt the Remuneration Report for the year ended 31 December 2008, by way of non binding vote."

The resolution was passed on a show of hands. The total number of proxy votes exercisable by all proxies validly appointed was 72,776,508. Instructions for the proxies were:

FOR	AGAINST	ABSTAIN	DISCRETIONARY
71,988,967	329,585	23,763	434,193*

* Including proxies held open in the name of the Chairman

Ordinary business item 3: Re-election of Director, Mr. Gary Garton.

"That Mr. Gary Garton, a Director, retiring in accordance with Clause 47.1 (b) of the Company's Constitution, being eligible, be re-elected as a Director of the Company."

The resolution was passed on a show of hands. The total number of proxy votes exercisable by all proxies validly appointed was 72,776,508. Instructions for the proxies were:

FOR	AGAINST	ABSTAIN	DISCRETIONARY
72,107,169	177,850	44,850	446,639*

* Including proxies held open in the name of the Chairman

David Young
Managing Director
Phone: (02) 9245 4460 or info@fermiscan.com.au



Fermiscan & Polartechnics proposed merger

Polartechnics Limited (Polartechnics, ASX:PLT) and Fermiscan Holdings Limited (Fermiscan, ASX:FER) announced on 17 April 2009 that they have agreed to a proposed merger.

The merger will be effected by Polartechnics making an off-market takeover offer (the 'Offer') for all the issued ordinary shares in Fermiscan. Polartechnics has also agreed to make individual offers to holders of Fermiscan options if certain conditions are met. Under the Offer, Polartechnics will offer three of its ordinary shares for every two Fermiscan ordinary shares. The individual offers to be made to holders of Fermiscan options will be on corresponding terms.

A full list of the conditions of the Offer was attached to the 17 April 2009 ASX announcement. Polartechnics and Fermiscan have agreed to co-operate on an exclusive basis in relation to the implementation of the Offer and have entered into an Implementation Agreement.

Polartechnics and Fermiscan intend to despatch the Bidder's Statement and the Target Statement by mid May 2009, with the Offer expected to be open for approximately one month from that date.

About Fermiscan

Fermiscan's principal activity is the commercialisation of an innovative non-invasive diagnostic test for the detection of breast cancer.

The Fermiscan Breast Cancer Test is based on the discovery by an Australian scientist that a change can be detected in the molecular structure of hair from women with breast cancer and this change can be identified by using diffraction of X-rays generated in a synchrotron.

Fermiscan completed a major clinical trial of the Fermiscan Test in May 2008, with sensitivity (ability to accurately detect cancer) of 74% in women under 70, and with a higher sensitivity for younger women; and specificity (ability to accurately detect the absence of cancer - negative predictive value) of 99.5%.

Fermiscan is developing opportunities to licence and sell the Fermiscan Test internationally, particularly in Australia, Europe, Japan, South East Asia, and the United States.

Fermiscan has recently granted an exclusive option agreement to licence the Fermiscan Test to Hitachi Chemical in Japan and Korea.

Fermiscan owns and operates the Sydney Breast Clinic, one of the largest diagnostic breast clinics in Australia that for more than 30 years has been caring for over 10,000 women annually.

With successful clinical trials concluded, commercialisation of the Fermiscan Test is progressing to plan in 2009.

Visit Fermiscan's website at www.fermiscan.com.au

Visit Polartechnics' website at www.polartechnics.com

Visit Sydney Breast Clinic's website at www.sydneybreastclinic.com.au